Abstract:Introduction: Human tumors, including gastric cancer, frequently express high levels of epidermal growth factor receptors (EGFRs), which are associated with a poor prognosis. Targeted delivery of anticancer drugs to cancerous tissues shows potential in sparing unaffected tissues. However, it has been a major challenge for drug penetration in solid tumor tissues due to the complicated tumor microenvironment. Chemotherapy employing paclitaxel (PTX) is widely used for treating various kinds of cancer including gastric cancer.Methods: Recombinant protein anti-EGFR-iRGD consisting of an anti-EGFR VHH (the variable domain from the heavy chain of the antibody) fused to iRGD, a tumor-specific binding peptide with high permeability were expressed in E. coli BL21 (DE3) and purified by nickel-nitrilotriacetic acid affinity chromatography. We use tumor cell lines (2D), multicellular spheroids (3D), and mice to analyze the antitumor activity of recombinant protein. To investigate the ability of anti-EGFR-iRGD to improve other drugs (e.g. PTX) penetrating into tumor, we used multicellular spheroids and mice.Results: We have successfully constructed a recombinant protein named anti-EGFR-iRGD, a dual target of EGFR and integrin and high permeable protein. It could spread extensively throughout both the multicellular spheroids and the tumor mass. The recombinant protein anti-EGFR-iRGD also exhibited antitumor activity in tumor cell lines (2D), multicellular spheroids (3D), and mice. Moreover, we demonstrated the therapeutic efficacy of PTX combined with anti-EGFR-iRGD on monolayer cells (2D), multicellular spheroids (3D) and tumor-bearing mice for the first time.Conclusion: Our results provide impetus for further studies for potentially using iRGD based fusion protein anti-EGFR-iRGD with standard cytotoxic treatment regimens for enhancing therapy of gastric cancer patients.Figure: P-014 Introduction: Human tumors, including gastric cancer, frequently express high levels of epidermal growth factor receptors (EGFRs), which are associated with a poor prognosis. Targeted delivery of anticancer drugs to cancerous tissues shows potential in sparing unaffected tissues. However, it has been a major challenge for drug penetration in solid tumor tissues due to the complicated tumor microenvironment. Chemotherapy employing paclitaxel (PTX) is widely used for treating various kinds of cancer including gastric cancer. Methods: Recombinant protein anti-EGFR-iRGD consisting of an anti-EGFR VHH (the variable domain from the heavy chain of the antibody) fused to iRGD, a tumor-specific binding peptide with high permeability were expressed in E. coli BL21 (DE3) and purified by nickel-nitrilotriacetic acid affinity chromatography. We use tumor cell lines (2D), multicellular spheroids (3D), and mice to analyze the antitumor activity of recombinant protein. To investigate the ability of anti-EGFR-iRGD to improve other drugs (e.g. PTX) penetrating into tumor, we used multicellular spheroids and mice. Results: We have successfully constructed a recombinant protein named anti-EGFR-iRGD, a dual target of EGFR and integrin and high permeable protein. It could spread extensively throughout both the multicellular spheroids and the tumor mass. The recombinant protein anti-EGFR-iRGD also exhibited antitumor activity in tumor cell lines (2D), multicellular spheroids (3D), and mice. Moreover, we demonstrated the therapeutic efficacy of PTX combined with anti-EGFR-iRGD on monolayer cells (2D), multicellular spheroids (3D) and tumor-bearing mice for the first time. Conclusion: Our results provide impetus for further studies for potentially using iRGD based fusion protein anti-EGFR-iRGD with standard cytotoxic treatment regimens for enhancing therapy of gastric cancer patients. Figure: P-014

RGD Peptides-Conjugated Pluronic Triblock Copolymers Encapsulated with AP-2α Expression Plasmid for Targeting Gastric Cancer Therapy in Vitro and in Vivo

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

Synergism of Rmv-Hu191 with Cisplatin to Treat Gastric Cancer by Acid Sphingomyelinase-Mediated Apoptosis Requiring Integrity of Lipid Raft Microdomains

Poly-γ-glutamic Acid-Based GGT-targeting and Surface Camouflage Strategy for Improving Cervical Cancer Gene Therapy.

Precise Targeting Therapy of Orthotopic Gastric Carcinoma by siRNA and Chemotherapeutic Drug Codelivered in pH‐Sensitive Nano Platform

Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment

A Novel Anti-Angiogenesis Peptide in Combination with Cisplatin Self-Assembling into Tube-Like Nanomedicine for Oral Treatment of Gastric Cancer

Targeting Effect of Pegylated Liposomes Modified with the Arg-Gly-Asp Sequence on Gastric Cancer

Enzyme‐Responsive Branched Glycopolymer‐Based Nanoassembly for Co‐Delivery of Paclitaxel and Akt Inhibitor toward Synergistic Therapy of Gastric Cancer

A Tumor-Penetrating Recombinant Protein Anti-Egfr-irgd to Enchance Efficacy of Paclitaxel in 3D Multicellular Spheroids and Gastric Cancer in Vivo.

Plga Nanoparticle-Based Docetaxel/Ly294002 Drug Delivery System Enhances Antitumor Activities Against Gastric Cancer

Target‑specific Delivery of Oxaliplatin to HER2‑positive Gastric Cancer Cells Inï¿½vivo Using Oxaliplatin‑au‑fe3o4‑herceptin Nanoparticles

Construction of Aptamer‐siRNA Chimera/PEI/5‐FU/Carbon Nanotube/Collagen Membranes for the Treatment of Peritoneal Dissemination of Drug‐Resistant Gastric Cancer

RGD Peptide-Mediated Chitosan-Based Polymeric Micelles Targeting Delivery for Integrin-Overexpressing Tumor Cells.

P-014A Tumor-penetrating Recombinant Protein Anti-Egfr-irgd Enhance Efficacy of Paclitaxel in 3D Multicellular Spheroids and Gastric Cancer in Vivo

Bioinspired ginsenoside Rg3 PLGA nanoparticles coated with tumor-derived microvesicles to improve chemotherapy efficacy and alleviating toxicity

Enhanced Efficacy of Gastric Cancer Treatment through Targeted Exosome Delivery of 17-DMAG Anticancer Agent

GX1-conjugated Poly(lactic Acid) Nanoparticles Encapsulating Endostar for Improved in Vivo Anticolorectal Cancer Treatment

Guanidyl and Imidazolyl Integration Group‐modified PAMAM for Gastric Adenocarcinoma Gene Therapy

Targeted delivery of 20(S)-ginsenoside Rg3-based polypeptide nanoparticles to treat colon cancer

Two Birds, One Stone: Dual Targeting of the Cancer Cell Surface and Subcellular Mitochondria by the Galectin-3-binding Peptide G3-C12